Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 8:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,016 matching trials from the live ClinicalTrials.gov search.
Filters: "chemoradiation" Clear all
Completed Phase 1 Interventional

Low Antioxidant Diet in Controlling Cachexia in Patients With Oropharyngeal Cancer Receiving Chemotherapy and Radiation Therapy

NCT00486304
View directory record Official record
Conditions
Cachexia, Head and Neck Cancer, Weight Changes
Interventions
ADD, Placebo
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 18, 2012 · Synced Oct 12, 2026, 8:41 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Lattice-Based Radiotherapy and Chemoimmunotherapy for Oropharyngeal Squamous Cell Carcinoma

NCT07428148
View directory record Official record
Conditions
Oropharyngeal Squamous Cell Carcinoma
Interventions
Induction Chemo-Immunotherapy, Lattice Radiotherapy
Drug · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Phase 3 Interventional Results available

Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery

NCT00424255
View directory record Official record
Conditions
Neoplasms, Head and Neck
Interventions
Lapatinib, Chemoradiation, Placebo
Drug · Radiation · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
688 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
5
States / cities
Springfield, Illinois • St Louis, Missouri • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2014 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Not applicable Interventional

A Nutritional Management Algorithm in Older Patients With Locally Advanced Esophageal Cancer

NCT02027948
View directory record Official record
Conditions
Localized Stage I-III Esophageal Cancer, Gastroesophageal Junction Cancer
Interventions
nutritional and functional assessments
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
65 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 12, 2026, 8:41 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma

NCT02998268
View directory record Official record
Conditions
Esophageal Adenocarcinoma
Interventions
Pembrolizumab, Taxol, Carboplatin
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 99 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Ann Arbor, Michigan • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Phase 3 Interventional Results available

Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer

NCT00052910
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
cisplatin, epirubicin hydrochloride, fluorouracil, leucovorin calcium, radiation therapy
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2016
U.S. locations
527
States / cities
Anniston, Alabama • Mobile, Alabama • Scottsdale, Arizona + 357 more
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Phase 3 Interventional Results available

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

NCT01013649
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraductal Papillary-Mucinous Neoplasm, Stage I Pancreatic Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7
Interventions
3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Capecitabine, Chemotherapy, Computed Tomography, Erlotinib Hydrochloride, Fluorouracil, Gemcitabine Hydrochloride, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Quality-of-Life Assessment, X-Ray Imaging
Radiation · Procedure · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
678
States / cities
Mobile, Alabama • Anchorage, Alaska • Auburn, California + 438 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 12, 2026, 8:41 PM EDT
Completed No phase listed Observational

Assessment of Treatment Response of Nasopharyngeal Cancer Using Simultaneous 18F-FDG-PET and MRI

NCT03656250
View directory record Official record
Conditions
Nasopharyngeal Cancer
Interventions
PET/CT scans
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Phase 1 Interventional

Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer

NCT00983268
View directory record Official record
Conditions
Pancreatic Cancer, Periampullary Adenocarcinoma
Interventions
capecitabine, vorinostat, Radiotherapy, Surgery to remove tumor
Drug · Radiation · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 15, 2015 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Not applicable Interventional Results available

Low-Level Laser Therapy for Prevention of Oral Mucositis

NCT02723604
View directory record Official record
Conditions
Mucositis
Interventions
Low Level Laser Therapy
Device
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 12, 2026, 8:41 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Dyadic Yoga Intervention for the Improvement of Healthcare Utilization and Quality of Life in Patients With Head and Neck Cancer Undergoing Chemoradiation and Their Caregivers

NCT04890834
View directory record Official record
Conditions
Head and Neck Carcinoma
Interventions
Best Practice, Exercise Intervention, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 12, 2026, 8:41 PM EDT
Recruiting No phase listed Observational

Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer

NCT04913311
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma
Interventions
Biospecimen Collection, Bronchoscopy with Bronchoalveolar Lavage, Chemoradiotherapy, Computed Tomography, Diagnostic Laboratory Biomarker Analysis, Immune Checkpoint Inhibitor, Nasal Wash and Collection, Quality-of-Life Assessment, Questionnaire Administration, Spirometry
Procedure · Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 12, 2026, 8:41 PM EDT
Recruiting Phase 2 Interventional

Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

NCT06592599
View directory record Official record
Conditions
Nasopharyngeal Carcinoma
Interventions
Toripalimab, Concurrent Chemoradiation and Adjuvant treatment following Chemoradiation
Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 12, 2026, 8:41 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer

NCT00573131
View directory record Official record
Conditions
Esophageal Cancer, Adenocarcinoma of the Esophagus, Squamous Cell Carcinoma
Interventions
OncoGel (Paclitaxel gel), cisplatin, 5-FU, radiation therapy, esophageal resection
Drug · Radiation · Procedure
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
8
States / cities
San Diego, California • Chicago, Illinois • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 12, 2026, 8:41 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

NCT04459715
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Xevinapant (Debio 1143), Cisplatin, Intensity Modulation Radiation Therapy (IMRT), Placebo
Drug · Radiation
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
44
States / cities
Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 12, 2026, 8:41 PM EDT
Terminated Not applicable Interventional Results available

Early Prediction of Pathology Response of Chemoradiotherapy With FLT PET

NCT01065818
View directory record Official record
Conditions
Esophageal Cancer, Non-small Cell Lung Cancer
Interventions
Fluoro-L-Thymidine
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Oct 12, 2026, 8:41 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC

NCT03141359
View directory record Official record
Conditions
Lung Cancer Stage II, Lung Cancer Stage III, Non Small Cell Lung Cancer
Interventions
SBRT, Carboplatin, Paclitaxel, cis Platinum, Etoposide, IMRT, Durvalumab
Radiation · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Phase 1 Interventional

Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

NCT02311920
View directory record Official record
Conditions
Gliosarcoma, Supratentorial Glioblastoma
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Temozolomide
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
11
States / cities
San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 12, 2026, 8:41 PM EDT
Terminated No phase listed Observational

Oropharyngeal Function After Radiotherapy With IMRT

NCT00506324
View directory record Official record
Conditions
Head and Neck Neoplasms
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
21 Years to 79 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 14, 2015 · Synced Oct 12, 2026, 8:41 PM EDT
Active, not recruiting Phase 2 Interventional

Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT01154920
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Paclitaxel, Carboplatin, Cetuximab, Docetaxel, Cisplatin, Fluorouracil, Radiotherapy (RT), Chemotherapy
Drug · Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 12, 2026, 8:41 PM EDT
Terminated Not applicable Interventional

Photoacoustic Imaging for Measuring Tumors and Normal Tissue in Patients With Head and Neck Cancer

NCT04110249
View directory record Official record
Conditions
Head and Neck Carcinoma, Head and Neck Lymph Node, Head and Neck Squamous Cell Carcinoma, Laryngeal Neoplasm, Radiation Therapy Recipient
Interventions
Photoacoustic Imaging, Transcutaneous Acupoint Electrical Stimulation
Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 12, 2026, 8:41 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

NCT03703297
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Durvalumab, Tremelimumab, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
34
States / cities
Tucson, Arizona • Santa Rosa, California • New Haven, Connecticut + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Esophagus or Stomach

NCT00009880
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
filgrastim, cisplatin, fluorouracil, paclitaxel, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
66
States / cities
Mobile, Alabama • Phoenix, Arizona • Duarte, California + 54 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 12, 2026, 8:41 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response

NCT05610163
View directory record Official record
Conditions
Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Locally Advanced Rectal Adenocarcinoma
Interventions
Capecitabine, 5-fluorouracil, Leucovorin calcium, Irinotecan, Oxaliplatin, Long Course Chemoradiotherapy, Computed Tomography, Magnetic Resonance Imaging, Sigmoidoscopy, biopsy
Drug · Radiation · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2037
U.S. locations
679
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 483 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 12, 2026, 8:41 PM EDT